Steven Prakken MD Chief, Medical Pain Service Duke Pain Medicine

Similar documents
Steven Prakken MD Director Medical Pain Service Duke Pain Medicine

Recognizing Narcotic Abuse and Addiction and Helping Those With It

USE OF BUPRENORPHINE FOR CHRONIC PAIN

Medications for the Treatment of Neuropathic Pain

Pain Management and Safe use of opioids in hospitals. Kyoung-Sil Kang, PharmD, BCPS Scott Tam, PharmD Lauve Casimir, RN, MSN

Objectives. When to Refer. PISA Physicians 1/25/17. Financial Disclosures: None. PISA & THMEP January 28, 2017 Kenneth B. Gossler M.D.

Prior Authorization Guideline

Pharmacy Medical Necessity Guidelines: Opioid Analgesics

Knock Out Opioid Abuse in New Jersey:

Non Malignant Pain: Symptom Management

SUMMARY OF ARIZONA OPIOID PRESCRIBING GUIDELINES FOR THE TREATMENT OF CHRONIC NON-TERMINAL PAIN (CNTP)

Persistent Pain Resources. Educational Slide Set

Best Practices in Prescribing Opioids for Chronic Non-cancer Pain

Analgesics: Management of Pain In the Elderly Handout Package

Practical Pain Management Leah Centanni, MSN, FNP-C, Asst. Clinical Professor CANP Conference March 22, 2014

Pain Management in a Geriatric Population. Alan Obringer RPh, CPh, CGP Executive Director Senior Care Pharmacy of Florida

Opiates & Opioids Opioids

EXTENDED RELEASE OPIOID DRUGS

Acute pain management in opioid tolerant patients. Muhammad Laklouk

AETNA BETTER HEALTH Prior Authorization guideline for Narcotic Analgesic Utilization

Understanding pain and mental illness Impact on management principles

Carefirst. +.V Family of health care plans

Lumbar Fusion. Reference Guide for PACU CLINICAL PATHWAY. All patient variances to the pathway are to be circled and addressed in the progress notes.

Long-Acting Opioid Analgesics

Long-Acting Opioid Analgesics

NATIONAL INSTITUTE FOR HEALTH AND CLINICAL EXCELLENCE SCOPE

Pain management. Coleman Palliative Care Conference: February 2016 Josh Baru MD Stacie Levine MD

OAT Transitions - focus on microdosing. Mark McLean MD MSc FRCPC CISAM DABAM

Blueprint for Prescriber Continuing Education Program

Neuropathic Pain. Scott Magnuson, MD Pain Management of North Idaho, PLLC

Choose a category. You will be given the answer. You must give the correct question. Click to begin.

Amber D. Hartman, PharmD Specialty Practice Pharmacist James Cancer Center & Solove Research Institute Ohio State University Medical Center

Vitamin D, TSH, free testosterone, B12, creatinine clearance, CRP, ESR. Test/rule out glucose intolerance with the 75g oral glucose test.

INFORMATION FOR PATIENTS. Let s Manage Pain

Canadian Guideline for Opioids for Chronic Non-Cancer Pain. Speaker Disclosure. Objectives. Canadian Guideline for Opioids for Chronic Non-Cancer Pain

Interprofessional Webinar Series

Opioid rotation or switching may be considered if a patient obtains pain relief with one opioid and is suffering severe adverse effects.

UCSF Pediatric Hospital Medicine Boot Camp Pain Session 6/21/14. Cynthia Kim and Stephen Wilson

PART VI: TAPERING OPIOIDS ROBERT JENKINSON MD MARCH 7, 2018

OPIOIDS. Questions about opioids, and the Answers that may SURPRISE YOU. A booklet for people who may benefit from reducing or stopping their opioid

OPIOIDS. Questions about opioids, and the Answers that may SURPRISE YOU. A booklet for people who may benefit from reducing or stopping their opioid

Slide 1. Slide 2. Slide 3. Opioid (Narcotic) Analgesics and Antagonists. Lesson 6.1. Lesson 6.1. Opioid (Narcotic) Analgesics and Antagonists

Canadian Guideline for Opioids for Chronic Non-Cancer Pain. Speaker Disclosure. Objectives. Canadian Guideline for Opioids for Chronic Non-Cancer Pain

Objectives. Controversy. Pain. Risk Stratification 1/7/2012

Diagnosis (Please be specific & provide as much information as possible):

CHAPTER 4 PAIN AND ITS MANAGEMENT

Responding to The Joint Commission Alert on Safe Use of Opioids in Hospitals

Pain Management Wrap-Up Chronic Care. David Tauben, MD Medicine Anesthesia & Pain Medicine

Drug Information Common to the Class of Extended-Release and Long-Acting Opioid Analgesics (ER/LA opioid analgesics) Avinza Butrans

Pain. November 1, 2006 Dr. Jana Pilkey MD, FRCP(C) Internal Medicine, Palliative Medicine

What Pharmacists Need to Know about Pain and its Management

Substances under Surveillance

Universal Precautions and Opioid Risk. Assessment. Questions: How often do you screen your patients for risk of misuse when prescribing opioids?

Prior Authorization for Opioid Products Indicated for Pain Management

Long-Acting Opioid. Policy Number: Last Review: 12/2017 Origination: 09/2013 Next Review: 09/2018

Opioid Analgesics. Recommended starting dose for opioid-naïve patients

Hospital Based Opioid Management A case based, peer discussion

Pain Management in Primary Care: Patient Selection, Analgesics, and Compliance Monitoring. Joshua D. Dion MSN, APRN-BC, ACNP

HOPE. Considerations. Considerations ISING. Safe Opioid Prescribing Guidelines for ACUTE Non-Malignant Pain

Management of Cancer Pain

Disclosures. You're in Control or Urine Control Clinical Pearls of Drug Testing Case Studies. 9/20/17

PALLIATIVE TREATMENT BY DR. KHRONGKAMOL SIHABAN MEDICAL ONCOLOGIST

OPIOIDS, BENZODIAZEPINES AND THE ELDERLY:

New Product to Market: Lonhala Magnair

12/14/2018. Disclosures. Buprenorphine. Drug-Receptor Interactions. Affinity

Overcoming challenges in pain management in older patients. David Lussier, MD, FRCP(c) March 21, 2012

Regional Renal Training

The Challenges of Opioid Dispensing

Analgesia for Patients with Substance Abuse Disorders. Lisa Jennings CN November 2015

A Patient s Guide to The Medication Approach to Chronic Pain

POST OPERATIVE PAIN MANAGEMENT: PAIN AND COMPLICATIONS

Fighting the Good Fight: How to Convert Opioids Just Right!

Opioid Review and MAT Clinic Comorbidities Associated with Opioid Overdose

Pain Management in the Elderly. Martha Watson, MS, APRN, GCNS Christie Bowser, RN-BC, RN

Mitigating Risks While Optimizing the Benefits of Pharmacologic Agents to Manage Pain in the Elderly

Session II. Learning Objectives for Session II. Key Principles of Safe Prescribing. Benefits and Limitations of ER/LA Opioids

1/26/2016. These are my own thoughts! Safe Workplace Safe Workforce Proven benefits of Stay At Work / Return To Work Process (SAW/RTW)

Christopher J. Earley, MB, BCh, PhD Professor Department of Neurology Johns Hopkins School of Medicine

Disclosures. Preventing, Recognizing and Managing Opiate Use Disorders. Opioids in the US 10/13/17

Tapering Opioids Best Practices*

4/3/2018. Management of Acute Pain Crises. Five Mistakes I ve made and why you shouldn t

Medical vs. Use of Drugs. Warning Signs of Chemical Dependence. Intent Effect. Legality Pattern 5/5/2010. Daily use above ceiling doses

Disclosures. Management of Chronic Pain for Cancer Survivors. University of Kentucky HealthCare, Lexington, KY

Monte H. Moore, MD. Idaho Physical Medicine and Rehabilitation. Meridian, ID

NEUROPATHIC CANCER PAIN STANDARDS AND GUIDELINES

Palliative Prescribing - Pain

Acute Pain NETP: SEPTEMBER 2013 COHORT

Buprenorphine pharmacology

Safe and Competent Opioid Prescribing

Policy on Pharmacological Therapies Practice Guidance Note Reducing Dosing Errors with Opioid Medicines V04

QUANTITY LIMIT AND POST LIMIT PRIOR AUTHORIZATION CRITERIA

Bree Collaborative AMDG Opioid Prescribing Guidelines Workgroup. Opioid Prescribing Metrics - DRAFT

Acute Pain Management in the Hospital Setting. Alexandra Phan, PharmD PGY-1 Pharmacy Practice Resident Medical Center Hospital Odessa, TX

CHAMP: Bedside Teaching TREATING PAIN. Stacie Levine MD. What is the approach to treating pain in the aging adult patient?

Caring for the Mind: Managing Depression and Anxiety. Highlights from 2017 ONS Congress

Pain Assessment & Management. For General Nursing Orientation

20/0.8mg, 30/1.2mg, Films 90 MME/day Belbuca (buprenorphine) 75mcg, 150mcg, 300mcg, 450mcg 60 units per 90 days

UnitedHealthcare Pharmacy Clinical Pharmacy Programs

MAT for Opioid Dependence. MAT and Pain Management. Epidemiology. Epidemiology. Factors Impacting Pain Perception 9/23/2014

Transcription:

Steven Prakken MD Chief, Medical Pain Service Duke Pain Medicine International Association for the Study of Pain "Pain is an unpleasant sensory and emotional experience associated with actual or potential tissue damage, or described in terms of such damage."

Constant aversive message that your body is damaged or being harmed No other medical condition like it due to Persistence Intrusiveness Behavior change unavoidable moment to moment Antithesis of the felt sense of control Struggling to regain somatic integrity Maslow s Hierarchy Be curious Let them teach you what they are doing Normalize behaviors Overuse, impulsivity Avoid playing gotcha Patient hiding in response Share control Establish clear limits Functional goals in pain Football field analogy 4

Pain alone, new onset sx s Constant intrusion on consciousness Catecholamine release Loss of control Role and relationship deterioration Financial deterioration Medication reactions Previous sx s enhanced by pain Personality SUD Previous mood/anxiety disorder Rumination, catastrophizing Depression rates in USA population 5% current, 6.7-9.5 % yearly, 20.8% lifetime Depression rates in pain 30-54% current, up to 65-80% lifetime Increased suicidal thoughts in depressed pain patients, up to 3 fold in CPP. Anxiety disorders rates in USA population 18.1% yearly, 28% lifetime Anxiety rates in pain Overall prevalence in pain ranges from 16.5% to 50% Fishbain 1999, Tang 2006, Raison 2009, Bair 2004, Knaster 2012

Lifetime prevalence in USA 16.7%, with ETOH at 13.5% and other drug use at 7% Prevalence in PAIN PATIENTS is quite varied, 2.8-28% current and 23-41% lifetime. Most commonly cited range is 4-26%. Some ways to predict and contain this risk Brown 1996, Cowan 2003, Michna 2004, ECA, Sehgal 2012, Functional Pharmacology Unexpected medication responses Opioid Stimulation Syndrome Misidentified sleep patterns Knowing safer opioids

Junker metaphor Can t fix your car Attachment to a fixed car will drive potentially risky interventions Procedural and pharmacologic Functional assessment Know what their days and nights actually look like Optimize somatic energy Pharmacologic assessment What all medications are actually doing Treating function, not just disease process Beneficial for disease, deleterious for function. Neuropathic agents Pregabalin, gabapentin, topiramate, etc Lamotrigine? Opioids Benzodiazepines Atypical medication reactions Expect sedation, get stimulation Opioids, topiramate, pregabalin, benzodiazepines, etc Expect stimulation, get sedation Stimulants, NE agents, etc

Sleep disturbance Sedative use/overuse Irritability Discharge from clinic Impulsivity Medication misuse Addiction Opioid induced hyperalgesia? Route 100% pill 45% crush/snort 62% chew 29% inject Motive for use 91% energy (100% women 83% men) 83% pain (100% women and 66% men) 82% euphoria/pleasure 50% stress 47% withdrawal Back PhD 2011

Oxycodone Hydrocodone Fentanyl Buprenorphine Tapentadol (Nucynta) Tramadol (Ultram) Oxymorphone Morphine Hydromorphone Methadone Most Stimulating Most Sedating Bed time, initiation time, out of bed time Poor initiation? Why and what doing. Waking through night? Why, when, how many times, re-initiate time Clock watching and normal sleep If actually out of bed, how long, what doing Napping Somatic Energy is sum of hours slept in 24

Bedtime 11-12 pm Initiation: Does not initiate until 1am First wakes: 2am Later stages: Sleep an hour and wakes, initiates again in 30-60 min, does this 2-3 times and is then up for the rest of the day. Naps: unable to Total sleep 2-3 hrs maximum Bedtime 11-12 pm Initiation: Does not initiate until 5am Up watching TV, internet First wakes: 7am for family Later stages: Back to sleep at 9am, sleeps well to 3-4pm. Up for family. Up and down through evening. Naps: at times in the PM with TV Total sleep 8-9 hrs minimum

Pain Tramadol (Ultram) SNRI primary Opioid minimal, in metabolite only Tapentadol (Nucynta) NE and full agonist 50-75mg = 10mg oxycodone clinically Buprenorphine Partial agonist, ceiling effect Transdermal Patch (Butrans) Buccal (Belbuca) Reduction or replacement of benzos Risk assessment SUD, pulmonary disease, sleep apnea, etc What is a reasonable level? Low vs high risk True and limited PRN Which benzo? Long vs short half life HS dosing removed? Replace benzo with pain med? (two-fer) Duloxetine, pregabalin, gabapentin, other neuropathic agent, TCA, etc

Are meds making them anxious? Opioid stimulating, benzo stimulating, chronic steroids, etc AD optimization or augmentation Dose adjustment Rotation to other AD Atypical antipsychotic Treat by other means Buspirone Beta blocker CBT/DBT Etc. Reduction or Replacement of Opioid What is a reasonable level? Safer opioids Bup, tapentadol, tramadol, How to reduce 5-20% per month Sleep studies Pain and function reassessment Need opioid? Interventional assessment Injection, surgery, PT again, etc Alternative pain tx Yoga, PT, acupuncture, coping skills, etc OTC medication

Are meds making them anxious? Opioid stimulating, benzo stimulating, chronic steroids, etc AD optimization or augmentation Dose adjustment Rotation to other AD Atypical antipsychotic Treat by other means Buspirone Beta blocker CBT/DBT Etc. Questions?